NSEPress Release23 Jun 2026 · 23 Jun 2026, 06:21 pm
Press Release
Honasa Consumer Limited · HONASA
✦ AI Summary▲ PositiveM&A
Honasa Consumer Limited (HCL) has announced the acquisition of a 58% majority stake in Fluence Pharma, a science-backed nutraceuticals company specializing in patented Cyclical Nutrition Therapy. This strategic move marks HCL's entry into the high-growth nutraceuticals market, particularly focusing on "inside-out" beauty solutions. HCL will establish a new subsidiary, Honasa Health Private Limited, to scale Fluence's B2C nutrition portfolio. Fluence Pharma reported approximately INR 40 Crore revenue with over 20% EBITDA margin in FY26.
Analysis Scores
Earnings Impact8/10
Growth Catalyst9/10
Governance Concern1/10
Regulatory Risk2/10
Balance Sheet Risk3/10
Liquidity Impact5/10
Market Sentiment8/10
Full Announcement
Honasa Consumer Limited has informed the Exchange regarding a press release dated Jun 23, 2026, titled "Honasa Consumer Limited Enters Nutraceuticals with Majority Stake Acquisition in Fluence Pharma".